Figure 1.

Etanercept in active rheumatoid arthritis (TEMPO trial): ACR responses at 52 weeks. *P < 0.01, P < 0.0001, versus placebo; P < 0.05, §P < 0.0001, versus etanercept. ACR, American College of Rheumatology; MTX, methotrexate; TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes. Reprinted with permission [16].

Moreland Arthritis Research & Therapy 2005 7(Suppl 3):S2-S8   doi:10.1186/ar1736